Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 463-471

  Reuveni, Debby ^a   Halperin, Drora ^a   Shalit, Itamar ^a,b   Priel, Esther ^c   Fabian, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Angiogenesis; Chemotherapy; Colon carcinoma; Etoposide; Moxifloxacin; Topoisomerase II

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; INTERLEUKIN 8; MOXIFLOXACIN; SULFORHODAMINE B; SURVIVIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CYTOTOXIN; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; CARCINOMA; CELL CYCLE; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZA COMPOUNDS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOTOXINS; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; HT29 CELLS; HUMANS; QUINOLINES;

EID: 77954162964     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000695     Document Type: Article

References (40)

1. Seminara P, Pastore C, Iascone C, et al: Mitomycin C and etoposide in advanced colorectal carcinoma - A clinical in vitro experience that focuses on the problem of schedule dependence in combination therapy. Chemotherapy 53: 218-225, 2007.
2. Tanaka T, Halicka HD, Traganos F, Seiter K and Darzynkiewicz Z: Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide. Cell Cycle 6: 371-376, 2007.
3. Baldwin EL and Osheroff N: Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363-372, 2005.
4. Fan JR, Peng A, Chen HC, Lo SC, Huang TH and Li TK: Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. DNA Repair 7: 452-463, 2008.
5. Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M and Usuki K: Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant 14: 1262-1269, 2008.
6. You B, Tranchand B, Girard P, et al: Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer 62: 261-272, 1998.
7. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 10: 1514-1521, 1998.
8. Braybrooke JP, O'Byrne KJ, Saunders MP, et al: A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Ann Oncol 8: 294-296, 1997.
9. Menichetti ET, Silva RR, Tummarello D, Miseria S, Torre U and Celerino R: Etoposide and mitomycin C in pretreated metastatic breast cancer. Tumori 75: 473-474, 1989. (Pubitemid 20064229)
10. Voog E, Merrouche Y, Trillet-Lenoir V, et al: Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 23: 614-616, 2000.
11. Planting AS, van der Burg ME, van der Bent MJ, de Boer-Dennert M, State G and Verweij J: Phase II study of a short course of weekly high dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. Br J Cancer 73: 1265-1267, 1996.
12. Posner M, Slapak CA, Browne MJ, et al: A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. Am J Clin Oncol 13: 455-458, 1990.
13. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG and Schuppan D: Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 86: 443-448, 2002. (Pubitemid 34185131)
14. Shalit I, Nasrallah N, Bar-On S and Rabau M: In-vitro effect of ciprofloxacin and ofloxacin on murine and human colon carcinoma cell lines. Drugs 49: 296-297, 1995.
15. Duewelhenke N, Krut O and Eysel P: Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother 51:54-63, 2006. (Pubitemid 46047687)
16. Bakshi RP, Galande S and Muniyappa K: Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol 36: 1-37, 2001. (Pubitemid 32202689)
17. Robinson MJ, Martin BA, Gootz TD, et al: Effects of quinolone derivatives on eukaryotic topoisomerase-II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 266: 14585-14592, 1991.
18. Bromberg KD, Burgin AB and Osheroff N: Quinolone action against human topoisomerase II alpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 42: 3393-3398, 2003.
19. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E and Shalit I: Moxifloxacin enhances the antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 95: 1038-1046, 2006. (Pubitemid 44606830)
20. Bendetz-Nezer S, Gazit A and Priel E: DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol 66: 627-634, 2004. (Pubitemid 39329262)
21. Har-Vardi I, Mali R, Breietman M, et al: DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties. Hum Reprod 22: 2183-2189, 2007. (Pubitemid 47241864)
22. Kaufmann SC and Svingen PA: Immunoblot analysis and band depletion assays. In: Methods in Molecular Biology. Protocols in DNA topology and topoisomerase, Part I; DNA Topology and Enzymes. Vol. 94. Mary-Ann Bjornsti and Neil Osheroff (eds). Humana Press Inc., Totowa, NJ, 253-268, 1999.
23. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461, 2006.
24. Jung YD, Nakano K, Liu W, Gallick GE and Ellis LM: Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 59: 4804-4807, 1999. (Pubitemid 29472880)
25. Cohen JJ: Apoptosis. Immunol Today 14: 126-130, 1993.
26. 2, in human leukemia cells. Biochem Pharmacol 63: 1325-1335, 2002.
27. Blau H, Klein K, Shalit I, Halperin D and Fabian I: Moxifloxacin but not azithromycin selectively inhibits IL-8, IL-6, ERK 1/2, JNK and NFκB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 292: L343-L352, 2007.
28. Reuveni D, Halperin D, Shalit I, Priel E and Fabian I: Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem Pharmacol 75: 1272-1281, 2008.
29. Altieri DC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
30. Li F and Altieri DC: The cancer anti-apoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 59: 3143-3151, 1999.
31. Jahnke U, Higginbottom K, Newland AC, Cotter FE and Allen PD: Cell death in leukemia: Passenger protein regulation by topoisomerase inhibitors. Biochem Biophys Res Commun 361: 928-933, 2007.
32. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
33. Gianani R, Jarboe E, Orlicky D, et al: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32: 119-125, 2001. (Pubitemid 32150638)
34. Grossman D, McNiff JM, Li F and Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113: 1076-1081, 1999. (Pubitemid 30013356)
35. Wall NR, O'Connor DS, Plescia J, Pommier Y and Altieri DC: Suppression of survivin phosphorylation on Thr(34) by flavopiridol enhances tumor cell apoptosis. Cancer Res 3: 230-235, 2003. (Pubitemid 36070444)
36. Bromberg KD, Burgin AB and Osheroff N: A two-drug model for etoposide action against human topoisomerase II alpha. J Biol Chem 278: 7406-7412, 2003.
37. Weiss T, Shalit I, Blau H, et al: Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NFκB and MAPK activation and synthesis of proinflammatory cytokines. Anti Microb Agents Chem 48: 1974-1982, 2004.
38. Shalit I, Halperin D, Haite D, et al: Anti-inflammatory effects of moxifloxacin on IL-8, IL-1β, and TNF-α secretion and NFκB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimic Chemother 57: 230-235, 2006. (Pubitemid 43160163)
39. Rolny C, Capparuccia L, Casazza A, et al: The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205: 1155-1171, 2008. (Pubitemid 351679690)
40. Amin DN, Bielenberg DR, Lifshits E, Heymach JV and Klagsbrun M: Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 76: 15-22, 2008.